ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
ADC Therapeutics announced the initiation of a Phase 1b clinical trial for ADCT-601 (mipasetamab uzoptirine), targeting AXL in patients with advanced solid tumors. The trial aims to assess ADCT-601's safety as a standalone and in combination with gemcitabine, particularly in sarcoma, a tumor resistant to current treatments. ADCT-601 has shown a manageable tolerability profile and promising preclinical synergy with gemcitabine. This advancement continues ADC Therapeutics' focus on improving cancer treatment through targeted antibody-drug conjugates.
- Phase 1b trial of ADCT-601 initiated, targeting AXL in advanced solid tumors.
- ADCT-601 shows manageable tolerability profile as a monotherapy.
- Preclinical studies indicate synergy with gemcitabine.
- None.
ADCT-601 binds to AXL, a cancer antigen expressed in solid tumors such as sarcoma and is associated with resistance to chemotherapy
ADCT-601 was observed to have a manageable tolerability profile as monotherapy in Phase 1a
Pre-clinical studies demonstrate anti-tumor activity and synergy with gemcitabine
LAUSANNE,
“We look forward to the continued evaluation of ADCT-601, our AXL-targeting ADC, in advanced solid tumors after having established a manageable tolerability profile in our Phase 1a dose escalation trial,” said
The Phase 1b open-label, dose-escalation and dose-expansion clinical trial evaluates the safety and tolerability of ADCT-601 as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors. The first arm of the trial will enroll approximately 18 patients with sarcoma, a tumor resistant to current available cancer treatments in which AXL is overexpressed. For more information about the Phase 1b trial, please visit www.clinicaltrials.gov (identifier NCT05389462).
About ADCT-601
ADCT-601 is composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using GlycoConnect™ technology (licensed from
About
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami,
ZYNLONTA® is a registered trademark of
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business and commercialization strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005171/en/
Investors
Eugenia.Litz@adctherapeutics.com
+44 7879 627205
amanda.hamilton@adctherapeutics.com
+1 917-288-7023
Media
maryann.ondish@adctherapeutics.com
+1 914-552-4625
Source:
FAQ
What is ADCT-601 and its clinical trial status?
What tumors are being targeted in the ADCT-601 trial?
What are the expected outcomes of the Phase 1b trial for ADCT-601?
What is the significance of targeting AXL with ADCT-601?